Peptide Library

Human study PLS-00047

Serum Mitochondrial Open Reading Frame of the 12S rRNA-c (MOTS-c) Dynamics as a Complementary Marker of Treatment Response in Newly Diagnosed Multiple Myeloma: A Prospective Analysis.

Prospective cohort · 29 participants enrolled · not included in the assessments (other)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Serum Mitochondrial Open Reading Frame of the 12S rRNA-c (MOTS-c) Dynamics as a Complementary Marker of Treatment Response in Newly Diagnosed Multiple Myeloma: A Prospective Analysis.primary · Cureus · 2025-11-30 · PMID 41479490 · DOI

Design and participants

Design
Prospective cohort
Population
Patients newly diagnosed with multiple myeloma receiving frontline treatment.
Conditions
Multiple myeloma
Planned enrollment (registry)
Not reported
Enrolled
29
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): Changes in serum MOTS-c after therapy may serve as complementary markers of clinical response in multiple myeloma. Standalone predictive capacity was limited, and validation in larger cohorts is needed.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • inappropriate endpoint: MOTS-c was measured as an endogenous serum biomarker rather than given as an intervention, so no treatment effect of MOTS-c can be inferred.
    • small or imprecise: Only 29 myeloma patients were analysed, and the authors note limited standalone predictive capacity.
    • abstract only: Only the abstract is available in the record. Methods, numeric results, funding and conflicts are not reported.
    • no control group: There was no comparison group that did not receive treatment, and the study did not test a MOTS-c intervention.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 41479490, abstract (Conclusions, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 41479490, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 41479490, abstract (Results, sentence 3) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 41479490, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 41479490, abstract (Objectives, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).